NICE rejects Novartis' Aimovig on data 'uncertainty' despite migraine benefits

26th September 2019 Uncategorised 0

Patient advocates celebrated the approval of Novartis’ migraine prevention drug Aimovig last year, but now England’s cost watchdog has ruled the drug’s benefits don’t warrant its costs. In a final appraisal, the National Institute of Health and Care Excellence ruled that data supporting the drug are insufficient to issue a positive recommendation.

More: NICE rejects Novartis' Aimovig on data 'uncertainty' despite migraine benefits
Source: fierce